TTI-101   Click here for help

GtoPdb Ligand ID: 12268

Synonyms: C188-9 [2] | TTI 101 | TTI101
Compound class: Synthetic organic
Comment: TTI-101(formerly C188-9) is an orally bioavailable STAT3 transcription factor inhibitor. It blocks the tyrosine residue phosphorylation by Janus kinase (JAK) that mediates STAT3 activation, leading to downregulation of STAT3-mediated gene expression. This mechanism of action is considered as a valid approach for the treatment of inflammation, fibrosis, and a range of cancers [1,3].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 104.24
Molecular weight 471.11
XLogP 6.29
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cc1)S(=O)(=O)Nc1cc(c(c2c1cccc2)O)c1c(O)ccc2c1cccc2
Isomeric SMILES COc1ccc(cc1)S(=O)(=O)Nc1cc(c(c2ccccc12)O)c1c(ccc2ccccc12)O
InChI InChI=1S/C27H21NO5S/c1-33-18-11-13-19(14-12-18)34(31,32)28-24-16-23(27(30)22-9-5-4-8-21(22)24)26-20-7-3-2-6-17(20)10-15-25(26)29/h2-16,28-30H,1H3
InChI Key QDCJDYWGYVPBDO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
TTI-101 was advanced as an oncology clinical lead.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03195699 Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers Phase 1 Interventional Tvardi Therapeutics, Incorporated
NCT05440708 A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma Phase 1/Phase 2 Interventional Tvardi Therapeutics, Incorporated
NCT05384119 Study of TTI-101 in Combination for Participants With Metastatic Hormone Receptor-Positive and Human Epithelial Receptor 2 (HER2)-Negative Breast Cancer Phase 1/Phase 2 Interventional Tvardi Therapeutics, Incorporated